Wednesday, August 24, 2016| Antibiotics, Auven Therapeutics, Dry Eye, Intravitreal Injection, Technology

EyewireTV — Dry Eye Drug Candidate Advances; Topical Antibiotics Study

In this week’s EyewireTV, Auven Therapeutics completes patient enrollment in a phase 3 confirmatory study of its dry eye disease drug candidate Seciera (OTX-101); and new research shows that topical antibiotics may be unnecessary in patients receiving intravitreous injections when povidone-iodine is used to prevent endophthalmitis. Also, a new vision simulator could help patients see how the world would look with each type of IOL before they have surgery.

Watch Video

Wednesday, August 17, 2016| Age-Related Macular Degeneration, Allergan, Cataract Surgery, Drug Delivery, ForSight Vision, Glaucoma, Research

EyewireTV — Interview with Allergan Executives; DED Reading Study

In this week’s EyewireTV, Allergan expands its glaucoma portfolio after agreeing to purchase ForSight Vision5, the maker of a noninvasive drug delivery platform; and a large study suggests that cataract surgery may have no clear link with the incidence of progression of age-related macular degeneration. In the feature, Allergan President and CEO Brent Saunders and Chief Commercial Officer Bill Meury talk to EyewireTV about a variety of topics, including the company’s research and development strategy, an update on its eye care pipeline, and the future of Restasis amid new competition.

Watch Video

Wednesday, August 10, 2016

EyewireTV – LASIK Satisfaction Study; Office-Based Cataract Surgery

In this week's EyewireTV, a large study finds that contact lens users who chose to have LASIK were more satisfied with their vision a year after the surgery ­ and remain satisfied over time; and ThromboGenics announces the 2-year results of the OASIS study evaluating the efficacy and safety of Jetrea (ocriplasmin) in patients symptomatic vitreomacular adhesion. Also, leading ophthalmologists share their opinions on the growing trend of performing office-based cataract surgery.

Watch Video

Wednesday, August 03, 2016| Alcon, CyPass Micro-Stent, FDA Approval/Clearance, Glaucoma, Macular Degeneration, Pixium Vision, Spectral-domain OCT, SD-OCT, Topcon Medical Systems

EyewireTV — FDA Approves MIGS Device; New OCT Technology in the US

In this week’s EyewireTV, the FDA approves Alcon's CyPass Micro-Stent system, a minimally invasive glaucoma surgical device for use in combination with cataract surgery; and Topcon Medical Systems receives FDA clearance for the 3D OCT-1 Maestro, which combines a high-resolution, color, nonmydriatic retinal camera with the latest spectral-domain OCT technology. Also, Pixium Vision receives the CE mark for its IRIS II bionic vision system, indicated for people with vision loss from outer retinal degeneration.

Watch Video

Wednesday, July 27, 2016| AcuFocus, Argus II Retinal Prosthesis System, Carl Zeiss Meditec, FDA Approval/Clearance, Ocular Therapeutix, Retinitis pigmentosa, Valeant

EyewireTV – Manufacturing Issues Stall Two Ophthalmic Drugs; New Leaders at Zeiss and AcuFocus

In this week's EyewireTV, citing manufacturing deficiencies, the FDA decides not to approve the new drug applications of two ophthalmic agents, Valeant Pharmaceuticals’ Vesneo (latanoprostene bunod ophthalmic solution 0.024%) and Ocular Therapeuitix’s Dextenza (dexamethasone insert 0.4 mg); and 5-year study results of the Argus II retinal prosthesis system indicate the device remains safe and beneficial for patients blind from retinitis pigmentosa. Also, James Mazzo is leaving AcuFocus, where he is chairman and CEO, to serve as the Global President of Ophthalmology at Carl Zeiss Meditec, and Alan Waterhouse is named the new President and Chief Operating Officer of AcuFocus.

Watch Video

Wednesday, July 20, 2016| Abbott Medical Optics, AMO, Allergan, Avedro, Cornea, Corneal Collagen Crosslinking, CXL, Corneal Ectasia, Dry Eye, FDA Approval/Clearance, Refractive Surgery, Tecnis Symfony IOL

EyewireTV - Tecnis Symfony IOL FDA Approved; New Cross-Linking Indication in US

In this week’s EyewireTV, the FDA approves Abbott’s Tecnis Symfony and Tecnis Symfony Toric IOLs, which the company says are the first extended depth of focus IOLs; and Avedro receives FDA approval for a second indication for its corneal collagen cross-linking platform—the treatment of corneal ectasia following refractive surgery. Also, Allergan files a de novo application with the FDA for the Oculeve Intranasal Tear Neurostimulator device, which is being investigated for temporarily increasing tear production upon activation in patients with dry eye disease.

Watch Video

Wednesday, July 13, 2016| Contact Lenses & Solutions, CooperVision, Dry Eye, FDA Approval/Clearance, Shire

EyewireTV - FDA Approves Xiidra (Lifitegrast) Dry Eye Treatment; CMS Reimbursement Rates

In this week’s EyewireTV, Shire receives FDA approval for its blockbuster dry eye treatment Xiidra (lifitegrast ophthalmic solution 5%), the only prescription eye drop indicated for the treatment of both the signs and symptoms of dry eye disease; and the Centers for Medicare and Medicaid Services issues its proposed calendar year 2017 payment rate regulation for hospital outpatient departments and ambulatory surgery centers. Also, CooperVision introduces Biofinity Energys, the first contact lenses specifically designed for digital device users.

Watch Video

Wednesday, July 06, 2016| Bausch+Lomb, Corneal Inlay, FDA Approval/Clearance, Medical Studies, Nicox , Posterior noninfectious uveitis, ReVision Optics, Uveitis

EyewireTV – FDA Approves Raindrop Inlay; Humira for Uveitis Treatment

In this week’s EyewireTV, ReVision Optics receives FDA approval for the Raindrop Near Vision Inlay, the first implantable device that changes the shape of the cornea to achieve improved vision; and the FDA approves Humira (adalimumab) for the treatment of noninfectious intermediate and posterior uveitis and panuveitis. Also, Bausch + Lomb and Nicox announce that the results of a phase 3 study of glaucoma drug candidate latanoprostene bunod have been published in the American Journal of Ophthalmology.

Watch Video

Wednesday, June 29, 2016| Allergan, FDA Approval/Clearance, Glaucoma, Myopia

EyewireTV - Myopia on the Rise in US; Rewarding Surgical Cases

In this week’s EyewireTV, a large, government-sponsored study estimates that nearly 10 million adults in the United States are highly myopic, with about one in 10 of those having a degenerative form of the disease; and the FDA accepts Allergan's 510(k) premarket notification application for the XEN Glaucoma Treatment System. In the feature, three leading eye care professionals describe the surgical cases they find most rewarding.

Watch Video

Wednesday, June 22, 2016

EyewireTV — Where’s Ophthalmology Headed? Hear from the Experts

In this week’s EyewireTV, leading ophthalmology researchers, clinicians, and entrepreneurs come together at OCTANE’s Orange County Technology Summit to discuss ground-breaking ophthalmic technologies, unmet clinical needs, and new business opportunities.

Watch Video

Wednesday, June 15, 2016| ArcScan, Diabetic Retinopathy, Diagnostics/Imaging, Eleven Biotherapeutics, Optical biometry, Roche, Ultrasound

EyewireTV - Major Diabetic Retinopathy Study Findings; ArcScan Insight 100 Launched

In this week’s EyewireTV, a National Institutes of Health-funded study (ACCORDION) of patients with type 2 diabetes shows less diabetic retinopathy progression among those who underwent intensive glycemic control; and Eleven Biotherapeutics enters into an exclusive license agreement with Roche for the rights to preclinical ocular drug technology in a deal worth up to $270 million. Also, the ArcScan Insight 100 ultrasound device for imaging and biometry of the eye is now commercially available and has been incorporated into the first US clinics.

Watch Video

Wednesday, June 08, 2016| American Society of Cataract & Ref Surgeons, ASCRS, Conjunctivitis, Intraocular lens, IOL, IOLs, IOL Selection, Ocular Therapeutix, Optovue, Retina

EyewireTV - Conjunctivitis Candidate Fails Late-Stage Trial; New Data-Driven IOL Calculator

In this week’s EyewireTV, in a second phase 3 trial, Ocular Therapeutix's lead product candidate Dextenza (sustained-release dexamethasone) fails to meet its primary endpoint for the treatment of ocular itching associated with chronic allergic conjunctivitis; and the American Society of Cataract and Refractive Surgery launches the Hill-RBF Calculator, a self-validating method for IOL power selection that employs pattern recognition and data interpolation. Also, Optovue announces the commercial availability of the AngioVue Retina imaging system, which provides practitioners with a noninvasive, dyeless way to visualize blood flow in the retina.

Watch Video
Load More